Trial · NCT03488251
Results by group13
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 13 of 13
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs) | Part 1: Cohort 1: MT-3724 10 mcg/kg/ GEM/ OX | 2 | Participants | ||
| Part 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Part 1 Cohort 1: MT-3724 10 mcg/kg/ GEM/ OX | TEAEs | 8 | Participants | |
| Part 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Part 1 Cohort 1: MT-3724 10 mcg/kg/ GEM/ OX | SAEs | 4 | Participants | |
| Part 1 and 2: Maximum Concentration (Cmax) Following Administration of MT-3724 | Part 1 Cohort 1: MT-3724 10 mcg/kg/ GEM/ OX | NA | Geometric Coefficient of Variation NA | Micrograms per milliliter | |
| Part 1 and 2: Area Under the Plasma Concentration Time Curve (AUC) Following Administration of MT-3724 | Part 1: Cohort 1: MT-3724 10 mcg/kg/ GEM/ OX | NA | Geometric Coefficient of Variation NA | Hours*micrograms per milliliter | |
| Part 1 and 2: Time to Maximum Plasma Concentration (Tmax) Following Administration of MT-3724 | Part 1: Cohort 1: MT-3724 10 mcg/kg/ GEM/ OX | NA | Full Range NA to NA | Hours | |
| Part 1 and 2: Number of Participants With Immunophenotyping Data Outside the Reference Range | Part 1: Cohort 1: MT-3724 10 mcg/kg/ GEM/ OX | NA | Participants | ||
| Part 1 and 2: Number of Participants With Anti-drug Antibody Titer | Part 1: Cohort 1: MT-3724 10 mcg/kg/ GEM/ OX | NA | Participants | ||
| Part 1 and 2: Number of Participants With Positive Neutralizing Antibodies | Part 1: Cohort 1: MT-3724 10 mcg/kg/ GEM/ OX | NA | Participants | ||
| Part 1 and 2: Objective Response Rate | Part 1: Cohort 1: MT-3724 10 mcg/kg/ GEM/ OX | 3 | Participants | ||
| Part 1 and 2: Disease Control Rate | Part 1: Cohort 1: MT-3724 10 mcg/kg/ GEM/ OX | NA | Participants | ||
| Part 1 and 2: Duration of Response | Part 1: Cohort 1: MT-3724 10 mcg/kg/ GEM/ OX | NA | Inter-Quartile Range NA to NA | Months | |
| Part 1 and 2: Progression-free Survival | Part 1: Cohort 1: MT-3724 10 mcg/kg/ GEM/ OX | NA | Inter-Quartile Range NA to NA | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03488251/results